[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline

Group salesgrow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding COVID-19 products,Group sales increase by 8%Pharmaceuticals Divisionsalesincrease by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Polivy (blood cancer)Diagnostics Division salesare 13% lower due to high demand for COVID-19 tests in 2022; strong momentum in theDiagnostics Division ’s base businesscontinues with an increase of 7%Highlightsin the fourth quarter of 2023 and January 2024:US approval ofVabysmo (retinal vein occlusion, a severe eye disease)US priority review ofXolair(food allergies)EU approval of subcutaneous form ofTecentriq(cancer immunotherapy)Positive phase III data forinavolisib(breast cancer),Xolair(food allergies) andHemlibra(babies with severe haemophilia A); positive longer-term data forColumviandLunsumio(blood cancer); positive long-term data forKadcyla(breast cancer)US Breakthrough Device Designation forElecsys NfLtest (multiple sclerosis); launch of innovativenew assays (hepatitis B and E)Acquisitions ofTelavant(inflammatory bowel disease and other immunologic disorders) andCarmot(obesity and other metabolic diseases);acquisition agreement withLumiraDx (point-of-care technol...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news